卵巢肿瘤患者血清CA125的检测及其意义.docVIP

卵巢肿瘤患者血清CA125的检测及其意义 【摘要】目的：探讨CA125检测在卵巢肿瘤患者中的临床意义。方法：应用免疫放射分析法（IRMA）测定75例恶性卵巢肿瘤（包括上皮性恶性卵巢肿瘤62例，非上皮性恶性卵巢肿瘤13例）、19例子宫内膜异位症、13例盆腔结缔组织炎、96例良性上皮性卵巢肿瘤、13例交界性卵巢肿瘤及52 例健康女性的血清CA125值，并结合其临床表现作统计学分析。结果：恶性上皮性卵巢肿瘤患者血清CA125值明显高于良性卵巢肿瘤、交界性卵巢肿瘤和非上皮性恶性卵巢肿瘤患者，差异有显著性（P0.01）；但与子宫内膜异位症、盆腔结缔组织炎患者血清CA125值比较差异无显著性（P0.05）；血清CA125的表达与上皮性恶性卵巢肿瘤的临床分期、化疗疗效密切相关（P0.01）。结论：血清CA125作为卵巢肿瘤标记物的重要指标，应在其诊断及治疗中常规检测。 【关键词】 卵巢肿瘤；CA125；肿瘤标记物 Detection of serum CA125 in patients with ovarian tumors YAN Zhaohua, MENG Jun (Department of Obstetrics and Gynecology, Affiliated Hospital of Guangdong Medical College, Zhanjiang 524001, China) 【Abstract】 Objective: To investigate the change of serum CA125 level and its clinical significance in patients with ovarian tumors. Methods: Serum CA125 level was determined by immunoradiometry in 75 patients with malignant ovarian tumors, 96 benign ovarian tumors, 13 borderline ovarian tumors, 19 endometriosis, 13 pelvic inflammation, and 52 healthy women. Results： Serum CA125 content in patients with epithelial ovarian cancers was significantly higher than those with nonepithelial ovarian cancers, benign ovarian tumors, and borderline ovarian tumors (P0.01), but it was not superior to that in patients with endometriosis and pelvic inflammation (P0.05). CA125 level was correlated with clinical staging and chemotherapeutic efficacy in epithelial ovarian cancers (P0.01). Conclusion: Serum CA125 maybe a marker for ovarian cancer. 【Key words】 ovarian tumor; CA125; tumor marker 卵巢肿瘤是女性生殖器常见肿瘤之一,卵巢恶性肿瘤又是女性生殖器三大恶性肿瘤之一。由于至今缺乏有效的诊断方法，卵巢恶性肿瘤的存活率仍较低，为25%～30%［1］。因此对卵巢恶性肿瘤的早期诊断和鉴别其良恶性、准确判断其治疗效果极为重要。本文应用免疫放射分析法（IRMA）测定52 例健康女性、216例盆腔包块及75例恶性卵巢肿瘤患者的血清CA125，并结合其临床表现作统计学分析，探讨CA125检测在卵巢肿瘤患者中的临床应用。 1 材料与方法 1.1 对象 216例入院诊断为盆腔包块的患者包括：子宫内膜异位症19例，盆腔结缔组织炎13例，良性上皮性卵巢肿瘤96例，交界性卵巢肿瘤组13例，恶性卵巢肿瘤75例（上皮性恶性卵巢肿瘤62例，非上皮性恶性卵巢肿瘤13例）。上皮性恶性卵巢肿瘤患者按 FIGO分期为：I期 8例，Ⅱ期 35例，Ⅲ期12例，Ⅳ期7例。62例上皮性恶性卵巢肿瘤患者术后常规行PC方案化疗，年龄22～72岁，中位年龄为53.5岁，临床资料完整。以门诊自愿检测血清CA125健康女性52 例为正常对照组。 1.2 方法 1.2.1 治疗方法 所有患者均先采用手术治疗，良性肿瘤经手术完全切除而治愈。上皮性恶